MedTrace Logo

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

NCT05515796 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2026-04-01

No results posted yet for this study

Summary

immunotherapy，gastric cancer，rectal cancer，biomark

Conditions

Interventions

DRUG

Terelizumab (aka Tislelizumab)

q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle

DRUG

CapeOx

Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

DRUG

Trastuzumab

q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle

RADIATION

Radiotherapy

25 Gy/5 fractions

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • wang bin · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2026-03-25
Completion
2026-03-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05515796 on ClinicalTrials.gov